Boston Scientific
Advancing science for life™

SYNERGY™
Everolimus-Eluting Platinum Chromium Coronary Stent System

Leading in Complex Patients
Short DAPT with the SYNERGY BP Stent

The SYNERGY BP Stent was intentionally designed with a fast-absorbing polymer to enable short DAPT

HEAL
WITH CONFIDENCE

SCAN ME
SYNERGY

This is a Dynamic Brochure
Scan QR Code with your
Smart Phone camera to learn more

STUDYING DAPT

SCAN ME

HBR SYMPO.

Leading in Short DAPT

Supporting well-constructed prospective Short DAPT clinical trials with over **5,000 patients** to study the SYNERGY™ BP Stent in different complex patient populations.†

SYNERGY BP Stent was Intentionally Designed to Enable Short DAPT and to Benefit High-Bleeding Risk Patients†

SENIOR*
1-month DAPT in stable elderly patients
6-month DAPT in ACS elderly patients

1,200 PATIENTS
SYNERGY BP Stent vs REBEL™ BMS

Region(s): Europe
Primary Endpoint: TCT 2017

2-Year Data Now Available

EVOLVE Short DAPT
3-month DAPT in HBR patients IDE Trial

2,009 PATIENTS
IDE Trial | SYNERGY BP Stent

Region(s): US, Europe, Japan, Brazil

0-3 Month Baseline Data Now Available

IDEAL Left Main*
4-month DAPT in SYNERGY BP Stent LM cohort
12-month DAPT in Xience™ PP Stent LM cohort

818 PATIENTS
SYNERGY BP Stent vs Xience PP Stent

Region(s): Europe, UK

Completed Enrollment

POEM*
1-month DAPT in HBR patients

1,023 PATIENTS
SYNERGY BP Stent

Region(s): Italy

Ongoing Enrollment

SYNIVUS-DAPT*
1-month DAPT in HBR patients

100 PATIENTS
SYNERGY BP Stent
IVUS

Region(s): US

Ongoing Enrollment

Reduced DAPT could minimize medication costs, complications and improve patient satisfaction

* Investigator-Sponsored Study. Boston Scientific is not responsible for the collection, analysis, or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific's involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products.
† Please review the SYNERGY DFU for full instructions on DAPT.

† Please review the SYNERGY DFU for full instructions on DAPT.

SENIOR TRIAL

HBR-Senior

1-Month and 6-Month DAPT in Elderly Patients

Safety Data at 2 Years

The SYNERGY™ BP Stent continued to show superior results versus REBEL™ BMS with short BMS-like DAPT regimen at 2 Years.

All Patients[1]

Low ARC Def/Prob
0.7% ST Rate
with SYNERGY BP Stent

Significant
65% ID-TLR
Reduction



1-Month DAPT Discontinuation Cohort †1

Low ARC Def/Prob
0.6% ST Rate
with SYNERGY BP Stent

Significant
79% ID-TLR
Reduction



SENIOR Trial is a randomized, single-blind trial evaluating the SYNERGY BP Stent and the REBEL BMS in patients 75 years or older with a short duration of DAPT. Over 50% of patients enrolled received a 1-month DAPT regimen.

Safety and Primary Endpoint Data at 1 Year

The SYNERGY BP Stent showed significantly lower MACCE‡ rates versus REBEL BMS at 1 year.

All Patients[2]

Low ARC Def/Prob
0.5% ST Rate
with SYNERGY BP Stent

Significant
70% ID-TLR
Reduction

Significant
29% MACCE
Reduction



1-Month DAPT Discontinuation Cohort†2,3

ZERO ST
with SYNERGY BP Stent after patient stopped DAPT at 1 month through 12 months

Significant
34% MACCE
Reduction

Significant
90% ID-TLR
Reduction



* Bleeding Academic Research Consortium (BARC).
† In patients eligible for 1-month DAPT in this study. Please review the SYNERGY DFU for full instructions on DAPT.
‡ SENIOR Trial Presented by Olivier Varenne, MD, at TCT 2018.

‡ All-cause mortality, MI, stroke, and ischemia-driven TLR.
[2] Varenne O, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomized single-blind trial. Lancet. 2018;391(10115):45-50. doi:10.1016/S0140-6736(17)32713-7.
[3] SENIOR Trial Presented by Olivier Varenne, MD, at EuroPCR 2018.

EVOLVE Short DAPT Trial

3-Month DAPT in High Bleeding Risk Patients

Clinical Outcomes at 3 Months[4]

The SYNERGY BP Stent showed extremely favorable outcomes in this complex patient group with significant bleeding risk:

Def/Prob ST: 0.3% | **TLR: 0.3%** | **Cardiac Death: 1.2%** | **MI: 1.4%**



The 3-month DAPT data is very encouraging and we look forward to the 15-month primary endpoint results to be reported in late 2019.

EVOLVE Short DAPT Trial is a multicenter, single-arm trial evaluating safety of 3-month DAPT regimen in High Bleeding Risk (HBR) patients in 2009 patients at over 110 global sites. 67% patients are elderly patients with age ≥75 years.

[4] Presented by Ajay Kirtane, MD at TCT 2018.

Continued DAPT Research

IDEAL Left Main Trial

Design	Randomized trial in real world all-comers population accepted for Left Main PCI with 4-month DAPT with SYNERGY BP Stent versus 12-month DAPT with XIENCE PP Stent.
Primary Endpoint	Rate of MACE defined as composite of death from any cause, MI, stroke and ischemia-driven Target Vessel Revascularization (TVR) at 2 years. Primary endpoint results to be reported in mid-2019.

POEM

Design	1-month DAPT in High Bleeding Risk (HBR) patients undergoing PCI with the SYNERGY BP Stent.
Primary Endpoint	Rate of MACE defined as composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 1 year.

SYNIVUS-DAPT

Design	1-month DAPT in HBR patients undergoing PCI with the SYNERGY BP Stent with intravascular ultrasound (IVUS).
Primary Endpoint	Rate of Cardiac Death and MI at 1 to 13 months.

"If you believe that short DAPT is preferable, we now have very strong evidence to select the SYNERGY Stent."
– Prof. Stefan James

SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

HEAL

WITH CONFIDENCE

IC-598002-AB-MAY2019 - CreativeServices

Boston Scientific

Advancing science for life™

www.bostonscientific-international.com

DINCAR2751EA